PRESS RELEASES

Found 234 Results
Page 3 of 24

Onxeo Expands its Pipeline with New Optimized Lead OX401 Entering Proof-of-Concept Preclinical Phase


OX401 is the second candidate utilizing Onxeo’s proprietary platform of decoy agonists, platON™ OX401 is optimized to be a next-generation […]

Tags:

06/20/2019


Onxeo renews its equity financing line with Nice & Green as part of the financing of its business and strategic activities


The new financing line could represent a total of approximately €9 million over the upcoming 12 months, based on current […]

Tags:

06/07/2019


Onxeo announces final positive data from DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors


Primary safety and activity endpoints met Favorable safety profile, maximum tolerated dose not reached, optimal active dose determined AsiDNA™ induced […]

Tags:

05/28/2019


Ordinary General Meeting of May 22, 2019


Renewal of the terms of office of Danièle Guyot-Caparros, Jean-Pierre Bizzari and Jean-Pierre Kinet Appointment of Danièle Guyot-Caparros as Chairman […]

Tags:

05/22/2019


Onxeo Announces Treatment of First Patient in DRIIV-1b, a Phase 1b Clinical Trial of AsiDNA™ in Combination with Chemotherapy


DRIIV-1b is designed to assess the clinical potential of AsiDNA™ in combination with carboplatin and with carboplatin plus paclitaxel in […]

Tags:

05/06/2019


Publication of the 2018 Registration Document


Paris (France), April 8, 2019 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]

Tags:

04/08/2019


Ordinary General Meeting on April 26, 2019


Paris (France), April 5, 2019 – 10 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]

Tags:

04/05/2019



Onxeo to Present Data supporting Lead Asset AsiDNA™ in 5 Poster Presentations at 2019 American Association for Cancer Research Annual Meeting


Paris (France), March 25, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

03/25/2019


Onxeo Reports Full-Year 2018 Financial Results and Provides Business Update


Clinical development of AsiDNA™ continues in phase 1 study DRIIV-1 Activity of AsiDNA™ demonstrated through the marked activation of its […]

Tags:

03/12/2019


Page 3 of 24

Last updated on